Key Highlights Semaglutide is a GLP-1 receptor agonist used for type 2 diabetes and obesity treatment, sold under Ozempic®, Wegovy®, and Rybelsus®.…
Sandoz
-
Active Pharmaceutical Ingredients (API)BrazilEuropeEurope Medicine Agency (EMA)Global MarketIndiaIntellectual Property (IP)JapanLaunchPatent LitigationPharma Science & ResearchRegulatoryU.S FDAUSA
-
Fungicide Resistance Action Committee (FRAC)RegulatoryResistance Action Committee (RAC)
FRAC 2024 POSTER PUBLISHED: INTRODUCTION OF TAVABOROLE ACTIVE INGREDIENT IN GROUP 54
by adminby adminMarch 2024, New poster is released by the Fungicide Resistance Action Committee (FRAC), revealing the inclusion of Group 54, Benzoxaboroles, in the…
-
CompaniesIntellectual Property (IP)Patent LitigationPatentsSandoz
Sandoz and Teva Invalidate Patent and SPC of Blockbuster Apixaban
by adminby adminSummary : EP 1,427,415 was assigned to BMS and is set to expire on September 17, 2022. On May 19, 2026, the…
-
CompaniesNovartis
Novartis signs initial agreement with Carisma Therapeutics for the manufacturing of HER 2 targeted CAR-M cell therapy
by adminby adminSummary : Novartis has signed an initial agreement with Carisma Therapeutics, a biopharmaceutical pioneer in engineered macrophage-based therapeutics, to manufacture the HER…
-
CompaniesGlobal MarketNovartis
Syncona announces sale of portfolio company to Novartis
by adminby adminSynopsis : Syncona – a company focused on founding, building and funding global leaders in life science – has announced the sale…
-
-
CompaniesGlobal MarketNovartis
Financials Indicate Novartis’ Sandoz Division Could Be a Tough Sell
by adminby adminSynopsis : Novartis reported its full-year financials this week for 2021, and overall, the news was good. Full-year net sales grew 4%,…
-
Agrochemicals
Amgen Wins its Second Patent of the year, Delaying Samsung’s Enbrel Biosim until 2029.
by adminby adminSummary – A U.S. District Court has ruled in favor of Amgen in a patent litigation case involving the drug Enbrel, preventing…
